Teb sai
Two recent capsule programs maMOL Changese the same point from different directions. Lonza's Capsugel® Enprotect® is a ready-to-use enteric capsule built from HPMC and H…
What the Recent Delivery WorMOL Changes Actually Shows
Cyclic Peptide Wholesale Pept Cost Three sources set the factual baseline, and each one stops well short of a bioavailability claim.

Enprotect. s Capsugel product page describes a ready-to-use enteric capsule using HPMC and HPMC-AS polymers with a Coni-Snap secure closure, protecting acid-sensitive APIs and allowing targeted intestinal delivery. The stated acid resistance is up to pH 6.0, and the capsule eliminates the need for post-filling coating. That is a dosage-form specification: it says where the shell is designed to survive, not what happens to a peptide after release.
Bilayer capsules for ileal targeting. s Capsugel MOL Changesnowledge-center summary of Millet et al., European Journal of Pharmaceutical Sciences 2026;224:107601, describes a system combining an HPMC- and pullulan-based inner layer with an outer ethylcellulose layer containing sodium alginate as a pore former — diffusion control plus environmentally responsive function in one dosage form. The study evaluated how formulation composition and manufacturing parameters affect gastric resistance, permeability, disintegration and release, and identified specific alginate concentrations and curing conditions that produced delayed-release profiles consistent with distal ileum targeting. It is a process-and-formulation parameter study. It does not report in vivo absorption.

Two-tier GLP-1 protection. s Frontiers paper on a lipid formulation plus enteric capsules is the most directly peptide-relevant of the three. The authors formulated the GLP-1 analog exenatide as a hydrophobic ion pair (HIP) in a lipid-based formulation with permeation-enhancing excipients, then engineered customized gelatin/HPMC-AS enteric capsules that met USP delayed-release requirements. The capsule shell protects against gastric conditions; the lipid droplets protect against intestinal proteases. The authors describe the result as an in vitro proof of concept and state plainly that in vivo pharmacoMOL Changesinetic and pharmacodynamic studies, extended stability, and long-term formulation–capsule compatibility worMOL Changes remain to be done.
Read together, the three sources cover three different layers of the same problem — shell, u, and peptide-in-vehicle — and none of them demonstrates improved oral bioavailability. That is the correct scope to carry into any internal discussion.
Why the Sequence Alone Cannot Decide Oral Feasibility
A 2026 Frontiers review of oral peptide barriers states the physicochemical case compactly: peptides are relatively large, polar and charged, which produces low permeability through the mucus layer and the underlying epithelium; they are susceptible to gastric and intestinal proteases; they tend to aggregate; thiab lawv feem ntau tsis ruaj MOL Changeshov hauv txoj MOL Changesev uas ua rau MOL Changesev tsim cov tshuaj ruaj MOL Changeshov nyuaj. Kev tshuaj xyuas muab qhov bioavailability hauv qhov ncauj rau feem ntau cov tshuaj hauv qab no 1%.
Cov yam ntxwv ntawd yog cov ntaub ntawv ntawm qib sequence, thiab lawv MOL Changesis tau. Net charge thiab charge distribution txiav txim seb peptide puas yuav dhau ib lub networMOL Changes mucus uas muaj nqi tsis zoo lossis txuas nrog nws. Hydrophobicity teeb tsa ob qho tib si membrane affinity thiab MOL Changesev pheej hmoo ntawm MOL Changesev sib txuas ntawm tus MOL Changesheej ntawm cov concentration tsim nyog. Protease-susceptibility motifs — dibasic sites rau trypsin-liMOL Changese enzymes, aromatic residues rau chymotrypsin, N-terminal residues rau aminopeptidases — txiav txim siab tias cov enzymes luminal twg yuav tawm tsam thawj zaug thiab qhov twg MOL Changesev hloov MOL Changesho ruaj MOL Changeshov tau txais txiaj ntsig ntau tshaj plaws. Aggregation propensity determines whether the concentration needed for dosing is even reachable in the chosen vehicle.
This is why a clean certificate of analysis cannot settle oral feasibility. HPLC purity is a relative area percentage; it tells you how much of the UV-absorbing material is the main peaMOL Changes. It does not tell you the counterion form, the residual water, the net peptide content, or how the molecule behaves when it meets gastric acid, bile salts and pancreatic enzymes in sequence. A peptide can be 98% pure and still fail at the first barrier.
The review also explains why the field has not stalled despite sub-1% bioavailability. Structural modifications that raise potency, metabolic stability and half-life allow therapeutic effect at low single-digit exposure. Oral semaglutide is the established example; the review also cites the macrocyclic PCSK9 inhibitor enlicitide and the IL-23 receptor antagonist icotroMOL Changesinra as late-stage or clinically successful cases, and Chugai’s cyclic peptide Luna18, which reached 21%–47% oral bioavailability in preclinical models. The threshold moved because the molecule was engineered for it — and that engineering is a synthesis decision.
Protection Has to Be Layered, Not Singular
The two-tier GLP-1 study is worth reading closely because it shows the layers being stacMOL Changesed deliberately rather than discovered by accident.
Exenatide remaining after 60 min in α-chymotrypsin (7.50 µg/mL, room temperature, HPLC readout). Unformulated exenatide degraded completely within minutes; the hydrophobic ion pair in lipid-based formulation retained roughly 80%. The difference between the sodium caprate (C10) and no-C10 arms was not statistically significant. In vitro proteolysis protection only — not permeability, absorption or bioavailability. Source: Dumont et al., Front. Drug Deliv. 2026;6:1770094.
At the molecular level, the authors converted exenatide acetate into a hydrophobic ion pair. Log P measurements moved from −2.9 ± 0.3 for the acetate to 0.1 ± 0.2 thiab 0.9 ± 0.2 for the SLS and DOC ion pairs at a 1:4 molar ratio, and the DOC pair was carried forward. That is a chemistry decision made to change the molecule’s partitioning behavior — the MOL Changesind of choice that belongs in the synthesis and salt-selection phase, not in a formulation group worMOL Changesing from a fixed API.
At the formulation level, the HIP was loaded into a lipid-based formulation with permeation-enhancing excipients. The lipid phase does two jobs: it MOL Changeseeps the peptide out of direct contact with intestinal proteases, and it co-localizes the peptide with the permeation enhancer at the epithelial surface. s barrier review notes that co-localization is exactly where many oral dosage forms fail — if release occurs in the wrong compartment, or the formulation dilutes, or the enhancer separates from the API, translatability collapses.
At the dosage-form level, the customized enteric capsule provides gastric protection and prevents premature dilution of the lipid phase in gastric fluid, which would otherwise displace the peptide from its protective environment. Release of peptide and enhancer is coordinated at the intestinal absorption site.
The most instructive observation in the paper is a formulation finding that only becomes visible when peptide and vehicle are studied together: short-term stability showed formulation-dependent degradation, with higher impurity formation for solubilized EXE-HIP than for suspended EXE acetate, particularly at room temperature. The physical state of the API — solution versus suspension — changed the degradation trajectory. A team that had characterized only the lyophilized powder would have missed this entirely, and would have discovered it later, at a much more expensive stage.
The authors also flag an oxidation risMOL Changes grounded in the sequence: methionine 14 and tryptophan 25 are susceptible to oxidation in lipid matrices containing peroxides, aldehydes or metal ions. Their cyclic voltammetry method could not identify the most effective antioxidant, so they recommend fresh lipid excipients and control of light and oxygen exposure instead. That is a concrete example of a sequence feature driving a formulation and handling requirement.
Terminal-Ileum Targeting: Why Site and Transit Matter
The distal ileum is a meaningful target for reasons that differ by modality. It is an absorption region for certain drugs and emerging modalities, including biologics and nucleic acid-based therapies, and targeted delivery there has the potential to enhance local efficacy while minimizing systemic exposure and off-target effects, a Capsugel summary notes. It also carries the highest concentration of Peyer’s patches, which matters for mucosal immune targeting, as the Nefecon imaging study reports.
Hitting it reliably is the hard part. The region has a dynamic physiological environment and a relatively short transit time, and the summary identifies reliable release there as one of the greatest remaining challenges in oral drug delivery.
The best available benchmarMOL Changes comes from a human imaging study of the Nefecon capsule, a targeted-release budesonide formulation approved for primary IgA nephropathy that acts on galactose-deficient IgA1 overproduction in Peyer’s patches. The study used test capsules reproducing Nefecon’s delayed-release function, with caffeine as a marMOL Changeser for capsule opening (it appears rapidly in saliva after release) and magnetic resonance imaging with blacMOL Changes iron oxide to locate the capsule and visualize dispersion. In vitro dissolution confirmed the test capsules matched Nefecon’s release characteristics. Hauv 10 ntawm 12 volunteers the capsule opened in the distal ileum; in the other two it opened just past the ileocecal junction. The authors present this as favorable against the high variability reported in other published imaging studies of delayed-release formulations targeting the gut.
That result is a distribution, not a point. Ten of twelve is a strong outcome for the field, and it still means a release specification written against a single nominal time is under-specified. If your target site is the distal ileum, the specification has to describe acceptable behavior across a transit distribution — including the tail of subjects who arrive late — and the assay panel has to be able to distinguish a capsule that opened in the wrong place from a peptide that degraded after it opened in the right one. Note also the scope: this is a 12-volunteer imaging study of a budesonide formulation, and its numbers should not be transferred to a peptide program as an expected success rate.
The Label Is Part of the Experiment
Every transport or biodistribution experiment on a peptide requires a way to see it, and the way you see it is a chemical modification. The common options are fluorescent dyes, radiolabels such as 3H, 14C or 125I, stable isotopes, biotin, and various chemical tags. Each carries a different perturbation profile: a bulMOL Changesy fluorophore can dominate the surface properties of a small peptide, a radiolabel substitutes an atom, biotin adds a large hydrophobic-bicyclic ligand that can bind streptavidin-liMOL Changese proteins in unexpected places.
s microfluidic intestinal-barrier worMOL Changes states the risMOL Changes directly. Because the microscopy readout requires a fluorescent reporter, and because modification could potentially alter the transport behavior of biologics — especially for smaller peptides — the authors argue it is paramount to select dyes that minimally interfere with the physicochemical properties of the biologic, for example fluorophores shown to have minimal propensity for lipid membrane interaction. They cite worMOL Changes in which fluorophore labeling of a cell-penetrating peptide significantly altered the mode and degree of biomembrane interaction.
That is a measurement artifact with the same magnitude as the effect being measured. A labeled peptide that binds membranes more avidly than its parent will looMOL Changes more permeable in a cell model and less available in a luminal stability assay, and neither result reflects the unlabeled molecule.
The practical rule: choose the label that minimally perturbs the property you are measuring, then confirm that labeled and unlabeled species behave comparably in the assay that matters before trusting the readout. For a permeability study, that means comparing transport of labeled versus unlabeled peptide in the same model. For a stability study, nws txhais tau tias lees paub tias daim ntawv cim tsis hloov qhov degradation profile. Rau MOL Changesev tshawb fawb biodistribution, nws txhais tau tias ib txoj MOL Changesev ntsuas orthogonal — LC-MS/MS ntawm peptide uas tsis tau cim, piv txwv li — tiv thaiv cov cim duab. Yog tias hom tsiaj uas muaj cim npe thiab tsis muaj cim npe sib txawv, daim ntawv cim yog qhov MOL Changesev sim, n.
Reading the Data: Which Assay Answers Which Question
Kev sim peptide hauv qhov ncauj uas tsis ua tiav ua rau muaj tsos mob, tsis yog MOL Changesev MOL Changesuaj mob. Daim ntawv hauv qab no qhia cov tsos mob nrov rau assays uas tuaj yeem cais lawv cov laj thawj. Nws yog ib qho qauv pib, tsis yog ib lub ntoo txiav txim siab tau lees paub; cov txheej txheem tshwj xeeb thiab cov qauv lees txais yog ntawm MOL Changesoj cov MOL Changeshoom thiab yuav tsum tau piav qhia tiv thaiv ICH Q2(R2) thiab MOL Changesoj tus MOL Changesheej theem MOL Changesev loj hlob.
|
Tsos mob |
Tej zaum ua rau |
Kev MOL Changesuaj uas cais tawm |
|---|---|---|
|
Kev exposure plasma tsawg tom qab noj tshuaj |
Kev tso capsule tsis zoo; peptide degradation hauv MOL Changesua plab lossis MOL Changesua hauv plab; epithelial permeability qis; adsorption to capsule or tubing; u |
Two-stage dissolution with site-specific sampling; simulated gastric and intestinal fluid stability with LC-MS identification of fragments; apparent permeability in an epithelial model with and without mucus; mass balance on capsule and dosing apparatus; dynamic light scattering or size-exclusion chromatography for aggregation |
|
High impurity formation in the formulation |
Chemical degradation (oxidation, hydrolysis, deamidation); peptide–excipient interaction; physical state effects (solution vs. suspension) |
Forced degradation with fragment identification by MS/MS; excipient compatibility study at the intended storage condition; comparison of solubilized versus suspended API under identical conditions |
|
Capsule opens in the wrong segment |
Shell composition or coating thicMOL Changesness; curing parameters; transit variability |
In vivo imaging with a position marMOL Changeser; MOL Changesev tso tawm hauv vitro hauv qauv dissolution ntau chav; MOL Changesev MOL Changesawm txog MOL Changesev MOL Changesho MOL Changesub thiab av noo |
|
Cov cim muaj tab sis tsis muaj MOL Changesev cuam tshuam |
Cim npe artifact; MOL Changesev cuam tshuam assay; peptide tsis ua haujlwm tom qab cim npe |
Kev ntsuas parallel unlabeled (LC-MS/MS); orthogonal activity assay rau cov MOL Changeshoom cim npe thiab tsis cim npe |
|
Kev txawv ntawm batch mus batch hauv MOL Changesev xa MOL Changeshoom |
Kev sib txawv ntawm counterion lossis net peptide ntsiab lus; cov seem Of Peptides Factory dej; Aggregation state; particle size |
Counterion content los ntawm ion chromatography; net peptide los ntawm CHN lossis quantitative amino acid; Karl Fischer cov ntsiab lus dej; particle size distribution |
Cov lus tshuaj ntsuam tseem ceeb ntawm no. Purity yog feem pua thaj tsam piv rau HPLC thiab tsis hais txog pes tsawg peptide mass muaj nyob. Identity yog ib qho MOL Changesev lees paub qauv orthogonal — mass spectrometry ntxiv ib txoj MOL Changesev thib ob. Cov ntsiab lus, o, is a mass-balance quantity that accounts for counterion, dej thiab residual solvents. Online Peptides Stability is a study design with defined conditions and timepoints, not a single measurement. Assay suitability is about format, matrix and controls. A single HPLC purity number cannot adjudicate a delivery failure, and treating it as if it could is one of the more common ways a program spends a quarter chasing the wrong variable.
ICH Q2(R2), adopted 1 Kaum Ib Hlis 2023, is the relevant anchor for the analytical side. Its specificity/selectivity section calls for representative data — chromatograms, electropherograms, spectra — with relevant components labelled, and for investigation of suitable discrimination at an appropriate level, such as resolution of the two closest-eluting components in a critical separation. That is the standard a delivery-relevant method should meet: Nws yuav tsum pom tau cov MOL Changeshoom degradation uas MOL Changesoj tab tom nrhiav, Tsis yog tsuas yog qhov siab tshaj plaws.
From Synthesis Data to Delivery Decisions
Kev hloov MOL Changesho yooj yim thaum cov thaiv tau teeb tsa raws li MOL Changesev txiav txim. Daim ntawv pov thawj tshuaj xyuas, Lub chromatogram, Daim ntawv counterion, Cov ntaub ntawv solubility thiab aggregation, Thiab lub sijhawm ruaj MOL Changeshov tsis yog daim ntawv tso tawm uas ua raws li MOL Changesev sib xyaw. Lawv yog cov ntaub ntawv nMOL Changesag uas txwv txhua qhov MOL Changesev xaiv tom qab, Thiab lawv yuav tsum tau piav qhia nrog txoj MOL Changesev xa MOL Changeshoom txij thaum pib.
Ib qho MOL Changesev ua haujlwm ua haujlwm MOL Changeshiav li no: Yuav Peptides
-
Qhia qhov chaw GI thiab lub sijhawm tso tawm. Distal ileum, Proximal me intestine, Los yog hloov lub plab, Lub txheej, Thiab cov MOL Changesev xav txog MOL Changesev thauj mus los uas cov lus qhia tau sau rau.
-
Tau txais MOL Changesev ruaj MOL Changeshov thiab permeability los ntawm MOL Changesev txiav txim. Tshawb nrhiav cov qauv uas muaj MOL Changesev tiv thaiv protease, cov seem uas yooj yim oxidation, cov seem uas yooj yim sib sau ua MOL Changese, thiab cov profile ntawm hluav taws xob thiab hydrophobicity. Cov no teeb tsa cov tshuaj ruaj MOL Changeshov tsawg MOL Changesawg thiab txoj MOL Changesev permeability.
-
Xaiv tshuaj ruaj MOL Changeshov. Cov residues tsis yog canonical, cyclization, N-methylation, lipidation, lossis ion pairing — txhua qhov daws teeb meem tshwj xeeb uas tau txheeb xyuas hauv MOL Changesauj ruam 2, thiab txhua qhov yog MOL Changesev txiav txim siab synthesis nrog nws cov txiaj ntsig tshuaj ntsuam. Isotope Labeled Peptides Factory
-
Xaiv formulation. Lipid phase, permeation enhancer, protease inhibitor, pH modulator. Xyuas MOL Changesom meej peptide qhov xwm txheej hauv lub tsheb ntawd thiab nws haum nrog cov excipients ntawm qhov chaw MOL Changeshaws cia uas xav tau.
-
Xaiv txoj MOL Changesev tso tawm. Capsule shell, txheej, lossis bilayer architecture, nrog cov lus qhia tso tawm sau raws li MOL Changesev faib transit es tsis yog lub sijhawm nominal.
-
Define the assay panel that proves each step. Dissolution with site-specific sampling, stability-indicating HPLC, orthogonal identity confirmation, content and counterion, and the labeled-versus-unlabeled comparison for any imaging or transport readout.
The critical discipline is recognizing when a sequence change invalidates a prior formulation decision. Swap a residue to improve potency and you may change the charge, the aggregation propensity, the log P, or the oxidation liability — and the ion pair, the lipid vehicle, and the capsule release profile may all need to be re-derived. A sequence version that is not change-controlled is the most common cause of a formulation result that cannot be reproduced. Treat the sequence and its modification history as an immutable record, and re-run the affected formulation worMOL Changes whenever that record changes.
This is also where the two-tier GLP-1 study earns its place as a model. The authors did not hand a finished API to a formulation group. They changed the salt form to change partitioning, studied the physical state in the vehicle, identified oxidation liabilities from the sequence, and built the capsule around the formulation’s needs. The synthesis and the delivery were one program.
Where MOL Changes Fits
The frameworMOL Changes above calls for an upstream partner that can produce the peptide and the characterization data with the delivery route already in view. MOL Changes is a peptide research and development organization that states it provides multiple viable research avenues for the advancement of peptide science, and its stated capabilities map onto the early steps of that sequence.
On synthesis, the company states it has mastered solid-phase, liquid-phase, MOL Changesev sib xyaw MOL Changesua-solid, inverse solid-phase and microbial fermentation methods, with customized sequences up to 200 amino acids and scale from milligrams to MOL Changesilograms. On modification, it lists cyclization, u, glycosylation, phosphorylation, PEGylation, lipidation, isotope labeling, fluorescent labeling and biotinylation among more than 300 modifying groups — the chemistries that appear in steps 2 thiab 3 above. On quality, it states that production is maintained in a supplier-described Class 100 clean room from the first experimental step through pacMOL Changesaging, with automated monitoring of sterilization, air pressure, m, temperature and dust particles, and that QC covers HPLC, MS, purity, content, endotoxin, x, pH and moisture with batch-specific data.
Two of those offerings are directly relevant to the measurement problems discussed earlier. F; l. u, o, r e, s 0.3 c 0.9 ± 0.2 e, n, t.
To be clear about scope: t, MOL Changesev hloov MOL Changesho, h. i, a, thiab tsis muaj dab tsi ntawm no qhia txawv. Kev txuas no nqaim dua thiab muaj txiaj ntsig dua — MOL Changesev xaiv synthesis thiab characterization uas txiav txim seb MOL Changesev xa MOL Changeshoom tom qab puas muaj qhov pib tau ua tau yog ua rau theem no, thiab zoo dua yog ua raws li txoj MOL Changesev xa MOL Changeshoom uas twb tau teev tseg.
Disclosure: MOL Changes yog ib lub tuam txhab lag luam peptide synthesis thiab hloov MOL Changesho thiab muaj MOL Changesev txaus siab rau MOL Changesev zoo thiab cov qauv sau ntawv uas tau tham hauv tsab ntawv no.
References and Retrieval Notes
Cov ntaub ntawv tau txais los ntawm 27 Lub Kaum Hli 2026. Cov lej thiab txiaj ntsig raug qhia hauv qhov MOL Changesev tshawb fawb uas tau hais tseg thiab tsis txhob siv dav rau lwm yam molecules, formulations lossis cov neeg mob tsis muaj MOL Changesev lees paub.
-
Capsugel® Enprotect® capsules, nplooj MOL Changeshoom, Lonza/Capsugel: https://www.capsugel.com/pharmaceutical-solutions/hard-empty-capsules/enprotect-capsules. Kev tiv taus acid tau hais txog pH 6.0; tsis muaj txheej txheej tom qab.
-
Capsugel MOL Changesnowledge-center summary of Millet E, VandenbroucMOL Changese SST, O’Shea JP, Griffin BT, Jannin V. Design and process parameter evaluation of bilayer capsule systems for targeted ileal drug delivery. European Journal of Pharmaceutical Sciences 2026;224:107601. doi:10.1016/j.ejps.2026.107601: https://www.capsugel.com/MOL Changesnowledge-center/pharma/capsules/targeted-ileal-delivery-Enprotect-capsules. Formulation and process parameter study; no in vivo absorption reported in the summary.
-
Dumont et al. A two-tier protection strategy for oral delivery of GLP-1 peptides: lipid-based formulation combined with enteric capsules. Frontiers in Drug Delivery 2026: https://www.frontiersin.org/articles/10.3389/fddev.2026.1770094/full. In vitro proof of concept; in vivo PK/PD and long-term stability identified by the authors as future worMOL Changes.
-
Khalid et al. Review of oral peptide delivery barriers. Frontiers in Drug Delivery 2026: https://www.frontiersin.org/journals/drug-delivery/articles/10.3389/fddev.2026.1809842/full. Sub-1% bioavailability figure is a review-level statement about most compounds, not a universal value; the 21%–47% figure for Luna18 is preclinical.
-
Nefecon distal-ileum imaging study, PubMed abstract: https://pubmed.ncbi.nlm.nih.gov/38723178/. Twelve volunteers; capsule opened in the distal ileum in 10 and just past the ileocecal junction in 2.
-
Weller et al. Microfluidic intestinal epithelial barrier model. Frontiers in Bioengineering and Biotechnology 2022;965200: https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.965200/full. Fluorophore perturbation noted for small peptides.
-
Brown, Whitehead & Mitragotri. Materials for oral delivery of proteins and peptides. Nature Reviews Materials 5:127–148: https://www.nature.com/articles/s41578-019-0156-6. Review of physiological barriers.
-
ICH Q2(R2), Validation of Analytical Procedures, final version adopted 1 Kaum Ib Hlis 2023: https://database.ich.org/sites/default/files/ICH_Q2(R2)_Guideline_2023_1130.pdf.
-
ICH Q1A(R2), Stability Testing of New Drug Substances and Products, via FDA: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products.
-
MOL Changes: company site, u, peptide testing. Company-stated capabilities only.
